The new collaboration between Japan’s Takeda and Montreal’s enGene will make use of enGene’s Gene Pill delivery platform to develop gene therapies for gastrointestinal diseases.
The technology has to ability to deliver either DNA or RNAi to mucosal tissues to either induce or suppress protein expression, for a given disease, whilst avoiding the efficiency issues and side effects brought about when administered through the bloodstream.
Under the terms of the agreement with Takeda, enGene will work on two undisclosed targets where Takeda will ultimately decide to license the candidates or not. EnGene will receive an upfront payment and reimbursement of all R&D costs. In addition, enGene will be eligible to earn milestone payments for the product candidates based on specific research, clinical, regulatory and commercial milestones. The two companies will also be working on using the Gene Pill technology to delivery antibodies orally where Takeda will have the exclusive option to obtain a right of first negotiation for up to three antibody targets.
“We are very excited to be collaborating with the team at Takeda to investigate new medicines for the specialty GI market using enGene’s innovative gene delivery platform for the gut,” said enGene CEO Anthony Cheung. “In addition to gaining non-dilutive funding to support the development of our own products, this alliance provides our company an excellent opportunity to grow our drug development capabilities through working with a leading pharmaceutical company in the gastroenterology space.”
Source: Takeda and enGene Establish Strategic Alliance to Develop Novel Therapeutics for Gastrointestinal Diseases; Press Release